# A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

> **NCT03412773** · PHASE3 · COMPLETED · sponsor: **BeiGene** · enrollment: 684 (actual)

## Conditions studied

- Hepatocellular Carcinoma (HCC)

## Interventions

- **DRUG:** Tislelizumab
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT03412773
- **Lead sponsor:** BeiGene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-12-18
- **Primary completion:** 2022-07-11
- **Final completion:** 2023-12-14
- **Target enrollment:** 684 (ACTUAL)
- **Last updated:** 2025-10-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03412773

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03412773, "A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03412773. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*